Aldeyra Therapeutics, Inc. (ALDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALDX Stock Price Chart Interactive Chart >
ALDX Price/Volume Stats
| Current price | $9.03 | 52-week high | $9.20 |
| Prev. close | $9.06 | 52-week low | $2.36 |
| Day low | $8.65 | Volume | 1,508,200 |
| Day high | $9.12 | Avg. volume | 490,537 |
| 50-day MA | $6.88 | Dividend yield | N/A |
| 200-day MA | $5.96 | Market Cap | 528.94M |
Aldeyra Therapeutics, Inc. (ALDX) Company Bio
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.
Latest ALDX News From Around the Web
Below are the latest news stories about ALDEYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate ALDX as an investment opportunity.
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis PigmentosaLEXINGTON, Mass., March 16, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. |
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call TranscriptAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After speakers’ presentations, there will be a question-and-answer session. I would […] |
Q4 2022 Aldeyra Therapeutics Inc Earnings CallQ4 2022 Aldeyra Therapeutics Inc Earnings Call |
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate HighlightsLEXINGTON, Mass., March 09, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2022. |
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal LymphomaLEXINGTON, Mass., March 02, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the New Drug Application (NDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of June 21, 2023. The FDA noted that no potential filing review issues have been identified. |
ALDX Price Returns
| 1-mo | 22.86% |
| 3-mo | 36.82% |
| 6-mo | 69.74% |
| 1-year | 86.19% |
| 3-year | 356.06% |
| 5-year | 8.14% |
| YTD | 29.74% |
| 2022 | 74.00% |
| 2021 | -41.69% |
| 2020 | 18.07% |
| 2019 | -30.00% |
| 2018 | 22.06% |
Loading social stream, please wait...